title: Aggregation, immune complexes and immunogenicity.
abstract: The development of an immune response to a protein therapeutic may nullify its beneficial activity or result in adverse events. Immunogenicity is, therefore, a major concern for clinicians, regulatory authorities and the biopharmaceutical industry. These concerns are particularly acute for the treatment of chronic diseases, as opposed to cancer, that may require repeated exposure to therapeutic over extended cycles of remission/relapse. There are many parameters that may be contributory to immunogenicity; however, the "bête noire," for the past decade has been aggregation. ( 1-3).
authors: Roy
authors: R
authors: Jefferis
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000276:immunology* / Q000627:therapeutic use; D000936:Antigen-Antibody Complex / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007109:Immunity / Q000187:drug effects* / Q000276:immunology; D007074:Immunoglobulin G / Q000737:chemistry* / Q000276:immunology* / Q000627:therapeutic use; D051379:Mice
chemical_list: D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G